Patents by Inventor Renate Parry
Renate Parry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240100361Abstract: Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.Type: ApplicationFiled: August 24, 2023Publication date: March 28, 2024Applicant: Varian Medical Systems, Inc.Inventors: Renate PARRY, Eric ABEL, Swati GIRDHANI, Stanley MANSFIELD, Patrick KUPELIAN, Deepak KHUNTIA
-
Patent number: 11771920Abstract: Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.Type: GrantFiled: September 27, 2021Date of Patent: October 3, 2023Assignee: Varian Medical Systems, Inc.Inventors: Renate Parry, Eric Abel, Swati Girdhani, Stanley Mansfield, Patrick Kupelian, Deepak Khuntia
-
Publication number: 20220008750Abstract: Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: VARIAN MEDICAL SYSTEMS, INC.Inventors: Renate PARRY, Eric ABEL, Swati GIRDHANI, Stanley MANSFIELD, Patrick KUPELIAN, Deepak KHUNTIA
-
Patent number: 11173325Abstract: Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.Type: GrantFiled: July 20, 2018Date of Patent: November 16, 2021Assignee: Varian Medical Systems, Inc.Inventors: Renate Parry, Eric Abel, Swati Girdhani, Stanley Mansfield, Patrick Kupelian, Deepak Khuntia
-
Publication number: 20210346719Abstract: A computing system comprising a central processing unit (CPU), and memory coupled to the CPU and having stored therein instructions that, when executed by the computing system, cause the computing system to execute operations to generate a radiation treatment plan. The operations include accessing a minimum prescribed dose to be delivered into and across the target, determining a number of beams and directions of the beams, and determining a beam energy for each of the beams, wherein the number of beams, the directions of the beams, and the beam energy for each of the beams are determined such that the entire target receives the minimum prescribed dose. A quantitative time-dependent model-based charged particle pencil beam scanning optimization is then implemented for FLASH therapy.Type: ApplicationFiled: July 22, 2021Publication date: November 11, 2021Inventors: Michael Matthew FOLKERTS, Jessica PEREZ, Christel SMITH, Eric ABEL, Anthony MAGLIARI, Reynald VANDERSTRAETEN, Timo Kalevi KOPONEN, Renate PARRY, Alexander KATSIS, Rajiv DUA, Michiko ALCANZARE, Perttu NIEMELA, Matti ROPO
-
Patent number: 11103727Abstract: A computing system comprising a central processing unit (CPU), and memory coupled to the CPU and having stored therein instructions that, when executed by the computing system, cause the computing system to execute operations to generate a radiation treatment plan. The operations include accessing a minimum prescribed dose to be delivered into and across the target, determining a number of beams and directions of the beams, and determining a beam energy for each of the beams, wherein the number of beams, the directions of the beams, and the beam energy for each of the beams are determined such that the entire target receives the minimum prescribed dose. A quantitative time-dependent model-based charged particle pencil beam scanning optimization is then implemented for FLASH therapy.Type: GrantFiled: June 11, 2019Date of Patent: August 31, 2021Assignees: Varian Medical Systems International AG, Varian Medical Systems Particle Therapy GmbH, Varian Medical Systems, Inc.Inventors: Michael Matthew Folkerts, Jessica Perez, Christel Smith, Eric Abel, Anthony Magliari, Reynald Vanderstraeten, Timo Kalevi Koponen, Renate Parry, Alexander Katsis, Rajiv Dua, Michiko Alcanzare, Perttu Niemela, Matti Ropo
-
Patent number: 11090508Abstract: Embodiments of the present invention provide an integrated solution to radiotherapy treatment planning that enables accurate recording and accumulation of physical parameters as input (e.g., dose, dose rate, irradiation time per voxel, etc.). User-defined functions are evaluated to correlate the input parameters with 4D biological outcomes. The resulting biological parameters can be visualized as a biological outcome map to evaluate decisions, support decisions, and optimize decisions regarding the parameters of the radiotherapy treatment plan, for example, for supporting clinical trials and related clinical research.Type: GrantFiled: March 8, 2019Date of Patent: August 17, 2021Assignees: Varian medical Systems Particle Therapy GmbH & Co. KG, Varian Medical Systems International AG, Varian Medical Systems, Inc.Inventors: Michael Matthew Folkerts, Jessica Perez, Christel Smith, Eric Abel, Anthony Magliari, Reynald Vanderstraeten, Timo Kalevi Koponen, Renate Parry, Alexander Katsis, Rajiv Dua, Michiko Alcanzare, Perttu Niemela, Matti Ropo
-
Publication number: 20210062277Abstract: The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.Type: ApplicationFiled: October 14, 2020Publication date: March 4, 2021Applicant: Varian Medical Systems, Inc.Inventor: Renate Parry
-
Patent number: 10844437Abstract: The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.Type: GrantFiled: March 6, 2018Date of Patent: November 24, 2020Assignee: Varian Medical Systems, Inc.Inventor: Renate Parry
-
Publication number: 20200282234Abstract: A computing system comprising a central processing unit (CPU), and memory coupled to the CPU and having stored therein instructions that, when executed by the computing system, cause the computing system to execute operations to generate a radiation treatment plan. The operations include accessing a minimum prescribed dose to be delivered into and across the target, determining a number of beams and directions of the beams, and determining a beam energy for each of the beams, wherein the number of beams, the directions of the beams, and the beam energy for each of the beams are determined such that the entire target receives the minimum prescribed dose. A quantitative time-dependent model-based charged particle pencil beam scanning optimization is then implemented for FLASH therapy.Type: ApplicationFiled: June 11, 2019Publication date: September 10, 2020Inventors: Michael Matthew FOLKERTS, Jessica PEREZ, Christel SMITH, Eric ABEL, Anthony MAGLIARI, Reynald VANDERSTRAETEN, Timo Kalevi KOPONEN, Renate PARRY, Alexander KATSIS, Rajiv DUA, Michiko ALCANZARE, Perttu NIEMELA, Matti ROPO
-
Publication number: 20200282233Abstract: Embodiments of the present invention provide an integrated solution to radiotherapy treatment planning that enables accurate recording and accumulation of physical parameters as input (e.g., dose, dose rate, irradiation time per voxel, etc.). User-defined functions are evaluated to correlate the input parameters with 4D biological outcomes. The resulting biological parameters can be visualized as a biological outcome map to evaluate decisions, support decisions, and optimize decisions regarding the parameters of the radiotherapy treatment plan, for example, for supporting clinical trials and related clinical research.Type: ApplicationFiled: March 8, 2019Publication date: September 10, 2020Inventors: Michael Matthew FOLKERTS, Jessica PEREZ, Christel SMITH, Eric ABEL, Anthony MAGLIARI, Reynald VANDERSTRAETEN, Timo Kalevi KOPONEN, Renate PARRY, Alexander KATSIS, Rajiv DUA, Michiko ALCANZARE, Perttu NIEMELA, Matti ROPO
-
Publication number: 20200155680Abstract: Methods for treating tumors by administering ionizing radiation and an immune modulator to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining immune modulators with ionizing radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with an immune modulator based on patient-specific biomarker signatures.Type: ApplicationFiled: November 25, 2019Publication date: May 21, 2020Applicant: Varian Medical Systems, Inc.Inventor: Renate Parry
-
Patent number: 10602991Abstract: An apparatus to examine a target in a patient includes an x-ray source configured to deliver a first x-ray beam towards the target, a device having an array of openings, the device located at an angle less than 180 degrees relative to a beam path of the first x-ray beam to receive a second x-ray beam resulted from an interaction between the first x-ray beam and the target, and a detector aligned with the device, the detector located at an angle less than 180 degrees relative to the beam path of the first x-ray beam to receive a part of the second x-ray beam from the device that exits through the openings at the device.Type: GrantFiled: March 29, 2012Date of Patent: March 31, 2020Assignee: Varian Medical Systems, Inc.Inventors: Edward J. Seppi, Renate Parry
-
Publication number: 20190022411Abstract: Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.Type: ApplicationFiled: July 20, 2018Publication date: January 24, 2019Applicant: VARIAN MEDICAL SYSTEMS, INC.Inventors: Renate Parry, Eric Abel, Swati Girdhani, Stanley Mansfield, Patrick Kupelian, Depak Khuntia
-
Publication number: 20180305769Abstract: The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.Type: ApplicationFiled: March 6, 2018Publication date: October 25, 2018Applicant: Varian Medical Systems, Inc.Inventor: Renate Parry
-
Publication number: 20180258181Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: March 5, 2018Publication date: September 13, 2018Applicant: Bayer Intellectual Property GmbHInventors: Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT
-
Patent number: 9938583Abstract: The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-? expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-? inhibitors with ionizing radiation to treat cancer patients.Type: GrantFiled: March 14, 2014Date of Patent: April 10, 2018Assignee: Varian Medical Systems, Inc.Inventor: Renate Parry
-
Publication number: 20170360932Abstract: Methods for treating tumors by administering ionizing radiation and an immune modulator to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining immune modulators with ionizing radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with an immune modulator based on patient-specific biomarker signatures.Type: ApplicationFiled: June 16, 2017Publication date: December 21, 2017Applicant: Varian Medical Systems, Inc.Inventor: Renate Parry
-
Publication number: 20160024594Abstract: The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-? expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-? inhibitors with ionizing radiation to treat cancer patients.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Inventor: Renate Parry
-
Publication number: 20150259433Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: March 11, 2015Publication date: September 17, 2015Inventors: Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT